NBIX Insider Trading

Insider Trading Chart
Insider Trading History
Frequently Asked Questions
About

Insider Ownership Percentage: 4.30%

Insider Buying (Last 12 Months): $0.00

Insider Selling (Last 12 Months): $67,321,906.82

Neurocrine Biosciences Insider Trading History Chart

Neurocrine Biosciences Share Price & Price History

^$141.91

▼ -0.09 (-0.06%)

As of 05/16/2024 01:00 AM ET

Days: 30 | 90 | 365

How Biden has already won 2024

From Porter & Company | Ad

Obama’s Forever Term [Exposed] or Obama Biden has already won 2024 Exposed: the shocking election plot that will forever enshrine Obama’s destructive, Marxist vision for America… A plot that could hand him and his allies near-total control over the government, your way of life, and your future.

Click here to watch this now before it’s too late.

Neurocrine Biosciences Insider Trading History

Transaction Date	Insider Name	Title	Buy/Sell	Number of Shares	Average Share Price	Total Transaction	Shares Held After Transaction
5/15/2024	Matt Abernethy	CFO	Sell	15,000	$140.24	$2,103,600.00	31,528
5/14/2024	Gary A. Lyons	Director	Sell	12,500	$135.63	$1,695,375.00	116,947
5/6/2024	Ingrid Delaet	Insider	Sell	273	$140.55	$38,370.15	7,507
4/15/2024	Eric Benevich	Insider	Sell	19,818	$133.36	$2,642,928.48	40,778
3/21/2024	Ingrid Delaet	Insider	Sell	5,000	$145.06	$725,300.00	7,507
3/14/2024	Eric Benevich	Insider	Sell	75,000	$139.38	$10,453,500.00	40,778
3/14/2024	George J. Morrow	Director	Sell	40,000	$139.42	$5,576,800.00
3/11/2024	Ingrid Delaet	Insider	Sell	200	$140.00	$28,000.00	7,507
3/11/2024	Richard F. Pops	Director	Sell	100	$140.00	$14,000.00	29,512
3/8/2024	Ingrid Delaet	Insider	Sell	1,800	$140.03	$252,054.00	7,507
3/8/2024	Richard F. Pops	Director	Sell	1,700	$140.05	$238,085.00	29,512
2/29/2024	Ingrid Delaet	Insider	Sell	273	$135.51	$36,994.23	7,507
2/27/2024	Leslie V. Norwalk	Director	Sell	8,000	$135.67	$1,085,360.00
2/20/2024	Richard F. Pops	Director	Sell	15,000	$132.47	$1,987,050.00	29,512
2/13/2024	Eiry Roberts	Insider	Sell	1,114	$132.96	$148,117.44	23,716
2/13/2024	Kevin Charles Gorman	CEO	Sell	2,832	$133.02	$376,712.64	514,596
2/13/2024	Matt Abernethy	CFO	Sell	1,352	$132.85	$179,613.20	31,528
2/8/2024	David W. Boyer	Insider	Sell	1,328	$135.41	$179,824.48	4,895
2/8/2024	Kevin Charles Gorman	CEO	Sell	2,274	$134.15	$305,057.10	506,962
2/8/2024	Matt Abernethy	CFO	Sell	980	$134.21	$131,525.80	30,314
2/6/2024	David W. Boyer	Insider	Sell	456	$141.96	$64,733.76	4,894
2/6/2024	Kevin Charles Gorman	CEO	Sell	3,040	$142.18	$432,227.20	504,919
2/6/2024	Matt Abernethy	CFO	Sell	1,280	$142.19	$182,003.20	29,434
1/31/2024	Eiry Roberts	Insider	Sell	1,457	$140.79	$205,131.03	20,832
1/31/2024	Kevin Charles Gorman	CEO	Sell	2,707	$140.69	$380,847.83	502,188
1/31/2024	Matt Abernethy	CFO	Sell	1,283	$140.72	$180,543.76	28,284
1/22/2024	Darin Lippoldt	Insider	Sell	10,000	$139.86	$1,398,600.00	35,882
1/8/2024	Kevin Charles Gorman	CEO	Sell	105,835	$132.44	$14,016,787.40	499,754
1/2/2024	Kyle Gano	Insider	Sell	75,000	$131.47	$9,860,250.00	130,250
1/2/2024	William H. Rastetter	Director	Sell	11,044	$131.47	$1,451,954.68	51,741
12/22/2023	Eiry Roberts	Insider	Sell	10,000	$126.74	$1,267,400.00	19,521
12/12/2023	Eiry Roberts	Insider	Sell	13,925	$120.30	$1,675,177.50	29,521
12/8/2023	Eiry Roberts	Insider	Sell	300	$120.10	$36,030.00	29,521
12/6/2023	Darin Lippoldt	Insider	Sell	20,830	$119.86	$2,496,683.80	35,882
12/1/2023	Gary A. Lyons	Director	Sell	5,000	$116.77	$583,850.00	203,697
11/29/2023	Jude Onyia	Insider	Sell	2,331	$113.57	$264,731.67	11,732
11/27/2023	Darin Lippoldt	Insider	Sell	10,919	$112.27	$1,225,876.13	35,882
10/2/2023	David W. Boyer	Insider	Sell	1,437	$112.68	$161,921.16	4,894
9/12/2023	Gary A. Lyons	Director	Sell	5,000	$115.02	$575,100.00	203,697
9/1/2023	Gary A. Lyons	Director	Sell	5,000	$110.06	$550,300.00	203,697
9/1/2023	Julie Cooke	Insider	Sell	824	$110.93	$91,406.32	17,263
8/30/2023	David W. Boyer	Insider	Sell	2,733	$107.60	$294,070.80	3,460
8/28/2023	Ingrid Delaet	Insider	Sell	1,431	$107.52	$153,861.12	5,931
8/21/2023	Jude Onyia	Insider	Sell	3,198	$107.37	$343,369.26	9,638
8/21/2023	Kevin Charles Gorman	CEO	Sell	9,328	$107.40	$1,001,827.20	499,754
8/21/2023	Matt Abernethy	CFO	Sell	2,132	$107.39	$228,955.48	27,131
5/1/2023	Julie Cooke	Insider	Sell	11,397	$103.89	$1,184,034.33	16,169
5/1/2023	William H. Rastetter	Director	Sell	4,300	$101.43	$436,149.00	42,785
4/24/2023	Eiry Roberts	Insider	Sell	14,400	$103.48	$1,490,112.00	26,644
4/21/2023	William H. Rastetter	Director	Sell	6,034	$105.04	$633,811.36	39,460
4/19/2023	William H. Rastetter	Director	Sell	903	$105.00	$94,815.00	34,729
2/23/2023	Neurocrine Biosciences Inc	Major Shareholder	Buy	4,395,588	$8.88	$39,032,821.44	8,575,316
2/8/2023	Eric Benevich	Insider	Sell	980	$104.12	$102,037.60	34,381
2/8/2023	Kevin Charles Gorman	CEO	Sell	2,274	$104.30	$237,178.20	491,365
2/7/2023	Matt Abernethy	CFO	Sell	26,328	$102.40	$2,695,987.20	24,333
2/6/2023	Eric Benevich	Insider	Sell	1,280	$105.63	$135,206.40	17,879
2/6/2023	Kevin Charles Gorman	CEO	Sell	3,040	$105.68	$321,267.20	468,008
1/31/2023	Eiry Roberts	Insider	Sell	1,457	$109.99	$160,255.43	26,171
1/31/2023	Kevin Charles Gorman	CEO	Sell	2,707	$110.08	$297,986.56	465,278
1/31/2023	Matt Abernethy	CFO	Sell	1,283	$109.98	$141,104.34	21,357
1/6/2023	Eric Benevich	Insider	Sell	400	$125.00	$50,000.00	15,643
1/3/2023	Stephen A. Sherwin	Director	Sell	30,000	$118.86	$3,565,800.00	25,055
11/30/2022	Eric Benevich	Insider	Sell	50,000	$125.90	$6,295,000.00	15,643
11/10/2022	Eric Benevich	Insider	Sell	100	$125.36	$12,536.00	15,643
11/8/2022	Eric Benevich	Insider	Sell	24,593	$125.33	$3,082,240.69	15,643
11/3/2022	Darin Lippoldt	Insider	Sell	4,518	$125.02	$564,840.36	29,234
11/1/2022	Darin Lippoldt	Insider	Sell	10,000	$120.09	$1,200,900.00	29,234
10/31/2022	Gary A. Lyons	Director	Sell	15,000	$114.76	$1,721,400.00	203,697
10/27/2022	Darin Lippoldt	Insider	Sell	4,923	$115.04	$566,341.92	29,234
10/17/2022	Eric Benevich	Insider	Sell	4,960	$110.82	$549,667.20	15,643
10/4/2022	Gary A. Lyons	Director	Sell	5,000	$110.54	$552,700.00	203,697
10/3/2022	David W. Boyer	Insider	Sell	1,437	$106.59	$153,169.83	4,214
8/12/2022	Malcolm Lloyd-Smith	Insider	Sell	21,533	$105.95	$2,281,421.35	18,888
6/27/2022	Julie Cooke	Insider	Sell	754	$100.00	$75,400.00	16,918
5/9/2022	Richard F. Pops	Director	Sell	15,000	$76.30	$1,144,500.00	29,512
4/25/2022	Gary A. Lyons	Director	Sell	15,000	$92.76	$1,391,400.00	208,697
4/1/2022	William H. Rastetter	Director	Sell	10,728	$94.93	$1,018,409.04	34,022
3/22/2022	Darin Lippoldt	Insider	Sell	8,455	$95.05	$803,647.75
3/18/2022	Darin Lippoldt	Insider	Sell	300	$95.00	$28,500.00
2/7/2022	David W. Boyer	Insider	Sell	240	$81.07	$19,456.80
2/7/2022	Kevin Charles Gorman	CEO	Sell	8,710	$80.82	$703,942.20
2/7/2022	Matt Abernethy	CFO	Sell	3,310	$80.79	$267,414.90
1/24/2022	Stephen A. Sherwin	Director	Sell	15,000	$74.43	$1,116,450.00
1/10/2022	Eiry Roberts	Insider	Sell	2,632	$74.50	$196,084.00
1/5/2022	Kyle Gano	Insider	Sell	28,266	$85.50	$2,416,743.00
12/1/2021	Matt Abernethy	CFO	Sell	1,645	$82.59	$135,860.55
10/7/2021	Dimitri E. Grigoriadis	Insider	Sell	8,000	$104.81	$838,480.00
10/7/2021	Gary A. Lyons	Director	Sell	5,000	$105.06	$525,300.00
10/4/2021	Julie Cooke	Insider	Sell	987	$101.73	$100,407.51
8/16/2021	Eric Benevich	Insider	Sell	5,628	$89.62	$504,381.36
7/27/2021	Malcolm Lloyd-Smith	Insider	Sell	16,709	$93.80	$1,567,304.20	15,801
6/10/2021	Gary A. Lyons	Director	Sell	10,000	$100.27	$1,002,700.00

Dems have chosen Biden replacement?

From Paradigm Press | Ad

On November 16, 2023… Joe Biden accidentally revealed the name of the candidate… Who will replace him in the 2024 presidential election.

See who it is HERE.

SEC Filings (Institutional Ownership Changes) for Neurocrine Biosciences (NASDAQ:NBIX)

92.59% of Neurocrine Biosciences stock is owned by institutions. Institutional ownership can be a sign of analyst confidence in the fundamentals of the stock.

Institutional Buying and Selling by Quarter

Neurocrine Biosciences Institutional Trading History

Reporting Date	Hedge Fund	Shares Held	Market Value	% of Portfolio	Quarterly Change in Shares	Ownership in Company
5/17/2024	Tidal Investments LLC	9,542	$1.32M	0.0%	+57.8%	0.009%
5/17/2024	Motley Fool Asset Management LLC	2,067	$0.29M	0.0%	+10.5%	0.002%
5/16/2024	Redwood Investment Management LLC	4,652	$0.64M	0.1%	N/A	0.005%
5/16/2024	California State Teachers Retirement System	144,405	$19.92M	0.0%	-0.2%	0.143%
5/16/2024	Meiji Yasuda Life Insurance Co	3,300	$0.46M	0.0%	N/A	0.003%
5/16/2024	Iron Triangle Partners LP	220,000	$30.34M	3.1%	N/A	0.219%
5/16/2024	Jacobs Levy Equity Management Inc.	712,798	$98.31M	0.4%	-5.3%	0.708%
5/16/2024	Janus Henderson Group PLC	1,378,513	$190.12M	0.1%	-11.1%	1.370%
5/16/2024	Kennedy Capital Management LLC	33,236	$4.58M	0.1%	+55.4%	0.033%
5/16/2024	Bayesian Capital Management LP	12,453	$1.72M	0.2%	+43.9%	0.012%
5/16/2024	Caxton Associates LP	18,528	$2.56M	0.1%	N/A	0.018%
5/15/2024	Sarissa Capital Management LP	346,426	$47.78M	8.4%	-26.3%	0.344%
5/15/2024	Public Employees Retirement System of Ohio	47,947	$6.61M	0.0%	+6.6%	0.048%
5/15/2024	Public Employees Retirement Association of Colorado	11,560	$1.59M	0.0%	-1.1%	0.011%
5/15/2024	Bellevue Group AG	2,055,874	$283.55M	4.3%	-15.4%	2.043%
5/15/2024	Hood River Capital Management LLC	227,998	$31.45M	0.7%	+7.3%	0.227%
5/15/2024	Lazard Asset Management LLC	55,329	$7.63M	0.0%	+19.1%	0.055%
5/15/2024	1832 Asset Management L.P.	36,800	$5.08M	0.0%	-10.2%	0.037%
5/15/2024	Truvestments Capital LLC	566	$78K	0.0%	+111.2%	0.001%
5/14/2024	Canada Pension Plan Investment Board	188,549	$26.01M	0.0%	+186.1%	0.187%
5/14/2024	Toronto Dominion Bank	9,963	$1.37M	0.0%	-25.0%	0.010%
5/14/2024	Sheaff Brock Investment Advisors LLC	1,878	$0.26M	0.0%	+11.7%	0.002%
5/14/2024	Advisors Asset Management Inc.	32,641	$4.50M	0.1%	+42.3%	0.032%
5/14/2024	CreativeOne Wealth LLC	7,953	$1.10M	0.0%	+257.8%	0.008%
5/14/2024	Delap Wealth Advisory LLC	2,796	$0.39M	0.2%	N/A	0.003%
5/14/2024	EntryPoint Capital LLC	516	$71K	0.1%	+76.1%	0.001%
5/14/2024	Vident Advisory LLC	97,754	$13.48M	0.3%	+3,756.2%	0.097%
5/14/2024	Shell Asset Management Co.	6,828	$0.94M	0.0%	+132.8%	0.007%
5/14/2024	Crewe Advisors LLC	700	$97K	0.0%	N/A	0.001%
5/14/2024	MQS Management LLC	3,998	$0.55M	0.3%	N/A	0.004%
5/14/2024	Natixis	1,581	$0.22M	0.0%	-17.0%	0.002%
5/14/2024	Healthcare of Ontario Pension Plan Trust Fund	21,660	$2.99M	0.0%	-69.5%	0.022%
5/14/2024	CANADA LIFE ASSURANCE Co	80,403	$11.09M	0.0%	-5.8%	0.080%
5/14/2024	American International Group Inc.	132,511	$18.28M	0.1%	-0.8%	0.132%
5/13/2024	UniSuper Management Pty Ltd	1,400	$0.19M	0.0%	+100.0%	0.001%
5/13/2024	Seven Eight Capital LP	1,672	$0.23M	0.0%	-76.8%	0.002%
5/13/2024	O Shaughnessy Asset Management LLC	3,695	$0.51M	0.0%	+16.8%	0.004%
5/13/2024	Ameritas Investment Partners Inc.	21,943	$3.03M	0.1%	+1.1%	0.022%
5/13/2024	PAX Financial Group LLC	9,947	$1.37M	0.3%	-4.2%	0.010%
5/11/2024	Covestor Ltd	1,744	$0.24M	0.2%	+8.5%	0.002%
5/11/2024	Edgestream Partners L.P.	24,005	$3.31M	0.2%	+71.4%	0.024%
5/10/2024	Ontario Teachers Pension Plan Board	28,812	$3.97M	0.0%	+72.9%	0.029%
5/10/2024	Acadian Asset Management LLC	3,466	$0.48M	0.0%	-88.9%	0.003%
5/10/2024	Vanguard Group Inc.	9,930,926	$1.37B	0.0%	+2.3%	9.868%
5/10/2024	Westfield Capital Management Co. LP	503,193	$69.40M	0.4%	-15.3%	0.500%
5/10/2024	Intech Investment Management LLC	24,186	$3.34M	0.0%	+97.2%	0.024%
5/10/2024	Mitsubishi UFJ Trust & Banking Corp	112,718	$15.55M	0.0%	-3.8%	0.112%
5/10/2024	Jupiter Asset Management Ltd.	218,466	$30.13M	0.3%	+4.0%	0.217%
5/10/2024	M&G Plc	69,026	$9.53M	0.1%	N/A	0.069%
5/10/2024	Cumberland Partners Ltd	3,000	$0.41M	0.0%	N/A	0.003%
5/10/2024	Twin Tree Management LP	19,147	$2.64M	0.0%	+59.4%	0.019%
5/9/2024	RFP Financial Group LLC	192	$26K	0.0%	+346.5%	0.000%
5/9/2024	Blair William & Co. IL	8,599	$1.19M	0.0%	+5.9%	0.009%
5/9/2024	Orion Portfolio Solutions LLC	28,965	$4M	0.0%	-1.7%	0.029%
5/9/2024	Scout Investments Inc.	106,525	$15.06M	0.4%	-59.3%	0.106%
5/9/2024	Mitsubishi UFJ Asset Management Co. Ltd.	55,194	$7.61M	0.0%	+34.0%	0.055%
5/9/2024	Fortis Capital Advisors LLC	4,236	$0.58M	0.2%	N/A	0.004%
5/9/2024	State Board of Administration of Florida Retirement System	109,446	$15.10M	0.0%	+2.0%	0.109%
5/8/2024	Motley Fool Asset Management LLC	8,188	$1.13M	0.0%	+337.9%	0.008%
5/8/2024	ProShare Advisors LLC	11,829	$1.63M	0.0%	+3.3%	0.012%
5/8/2024	Russell Investments Group Ltd.	349,317	$48.18M	0.1%	-13.8%	0.347%
5/8/2024	QRG Capital Management Inc.	15,878	$2.19M	0.0%	+9.3%	0.016%
5/8/2024	Headlands Technologies LLC	198	$27K	0.0%	-87.3%	0.000%
5/8/2024	Inspire Investing LLC	12,296	$1.70M	0.2%	+96.7%	0.012%
5/8/2024	Donoghue Forlines LLC	1,851	$0.26M	0.1%	+19.6%	0.002%
5/7/2024	Sei Investments Co.	86,669	$11.95M	0.0%	-25.3%	0.086%
5/7/2024	Concurrent Investment Advisors LLC	2,203	$0.30M	0.0%	-12.5%	0.002%
5/7/2024	Swiss National Bank	294,200	$40.58M	0.0%	-3.6%	0.292%
5/7/2024	Forsta AP Fonden	34,200	$4.72M	0.0%	+94.3%	0.034%
5/7/2024	ClariVest Asset Management LLC	9,594	$1.32M	0.1%	-0.8%	0.010%
5/7/2024	Lisanti Capital Growth LLC	6,650	$0.92M	0.2%	-1.6%	0.007%
5/7/2024	Oppenheimer Asset Management Inc.	13,421	$1.85M	0.0%	-13.3%	0.013%
5/7/2024	Oppenheimer & Co. Inc.	16,955	$2.34M	0.0%	-1.2%	0.017%
5/7/2024	Empowered Funds LLC	7,827	$1.08M	0.0%	-62.8%	0.008%
5/6/2024	Grandfield & Dodd LLC	15,594	$2.15M	0.1%	+1.3%	0.015%
5/6/2024	Texas Permanent School Fund Corp	87,087	$12.01M	0.1%	+2.6%	0.087%
5/3/2024	Mediolanum International Funds Ltd	9,804	$1.35M	0.0%	N/A	0.010%
5/3/2024	BI Asset Management Fondsmaeglerselskab A S	4,937	$0.68M	0.0%	+33.4%	0.005%
5/3/2024	Central Pacific Bank Trust Division	6,300	$0.89M	0.1%	N/A	0.006%
5/2/2024	Jennison Associates LLC	345,446	$47.64M	0.0%	-23.5%	0.347%
5/2/2024	Mutual of America Capital Management LLC	59,290	$8.18M	0.1%	-2.3%	0.060%
5/2/2024	Daiwa Securities Group Inc.	8,590	$1.19M	0.0%	+32.5%	0.009%
5/2/2024	Fidelis Capital Partners LLC	718	$99K	0.0%	N/A	0.001%
5/2/2024	Tobam	178,253	$24.59M	2.2%	-21.4%	0.179%
5/2/2024	Tokio Marine Asset Management Co. Ltd.	3,755	$0.52M	0.0%	+23.2%	0.004%
5/1/2024	Capstone Investment Advisors LLC	5,652	$0.78M	0.0%	+136.1%	0.006%
5/1/2024	Janney Montgomery Scott LLC	8,907	$1.23M	0.0%	+3.1%	0.009%
5/1/2024	BNP Paribas Financial Markets	431,982	$59.58M	0.1%	+40.4%	0.434%
5/1/2024	Mirae Asset Global Investments Co. Ltd.	13,300	$1.83M	0.0%	-50.7%	0.013%
5/1/2024	Mission Wealth Management LP	1,725	$0.24M	0.0%	-4.2%	0.002%
5/1/2024	Smith Group Asset Management LLC	48,114	$6.64M	0.4%	-29.7%	0.048%
4/30/2024	Retirement Systems of Alabama	124,955	$17.23M	0.1%	+1.5%	0.126%
4/30/2024	Norden Group LLC	2,848	$0.39M	0.0%	N/A	0.003%
4/30/2024	Van ECK Associates Corp	92,243	$12.72M	0.0%	+1,325.5%	0.093%
4/30/2024	Caprock Group LLC	1,560	$0.22M	0.0%	N/A	0.002%
4/30/2024	Claret Asset Management Corp	1,451	$0.20M	0.0%	-7.3%	0.001%
4/30/2024	Allspring Global Investments Holdings LLC	506,666	$69.88M	0.1%	+23.5%	0.509%
4/29/2024	Commonwealth Equity Services LLC	13,941	$1.92M	0.0%	+0.6%	0.014%
4/29/2024	Principal Financial Group Inc.	418,675	$57.74M	0.0%	+0.1%	0.421%
4/29/2024	Summit Global Investments	49,477	$6.82M	0.5%	+21.5%	0.050%

Data available starting January 2016

Neurocrine Biosciences, Inc. discovers, develops, and markets pharmaceuticals for neurological, neuroendocrine, and neuropsychiatric disorders in the United States and internationally. The company's products include INGREZZA for tardive dyskinesia and chorea associated with Huntington's disease; ALKINDI for adrenal insufficiency; Efmody capsules for classic congenital adrenal hyperplasia; Orilissa tablets for endometriosis; and Oriahnn capsules to treat uterine fibroids. Its product candidates in clinical development include valbenazine to treat dyskinetic cerebral palsy in pediatrics and adults; NBI-921352 to treat developmental and epileptic encephalopathy syndrome in pediatrics and adults; NBI-827104 to treat epileptic encephalopathy with continuous spike-and-wave during sleep; NBI-1076986 to treat movement disorders; crinecerfront to treat congenital adrenal hyperplasia in adults and children; EFMODY to treat congenital adrenal hyperplasia and adrenal insufficiency in adults; valbenazine for the adjunctive treatment of schizophrenia; NBI-1065845 for the treatment of inadequate response to treatment in major depressive disorder; luvadaxistat to treat cognitive impairment related to schizophrenia; NBI-1117568 for the treatment of schizophrenia; NBI-1070770 to treat major depressive disorder; NBI-1117570 for the treatment of symptoms of psychosis and cognition in neurological and neuropsychiatric conditions; and NBI-1117569, NBI-1117567, and NBI-1065890 to treat CNS indications. The company also has license and collaboration agreements with Heptares Therapeutics Limited; Takeda Pharmaceutical Company Limited; Idorsia Pharmaceuticals Ltd; Xenon Pharmaceuticals Inc.; Voyager Therapeutics, Inc.; BIAL Portela & Ca, S.A.; Mitsubishi Tanabe Pharma Corporation; and AbbVie Inc. The company was incorporated in 1992 and is headquartered in San Diego, California.

Today's Range

Now: $141.91

$140.17

$142.30

50 Day Range

MA: $138.37

$131.74

$143.74

52 Week Range

Now: $141.91

$89.04

$148.37

Volume

663,808 shs

Average Volume

832,741 shs

Market Capitalization

$14.28 billion

P/E Ratio

39.09

Dividend Yield

N/A

Beta

0.28

Who are the company insiders with the largest holdings of Neurocrine Biosciences?: Neurocrine Biosciences' top insider shareholders include:
Neurocrine Biosciences Inc (Major Shareholder)
Kevin Charles Gorman (CEO)
Gary A Lyons (Director)
Kyle Gano (Insider)
William H Rastetter (Director)
Eric Benevich (Insider)
Darin Lippoldt (Insider)
Matt Abernethy (CFO)
Eiry Roberts (Insider)
Richard F Pops (Director)
Stephen A Sherwin (Director)
Malcolm Lloyd-Smith (Insider)
Julie Cooke (Insider)
Jude Onyia (Insider)
Ingrid Delaet (Insider)
David W Boyer (Insider)
George J Morrow (Director)
Leslie V Norwalk (Director)
Learn More about top insider investors at Neurocrine Biosciences.
Who are the major institutional investors of Neurocrine Biosciences?: Neurocrine Biosciences' top institutional investors include:
Vanguard Group Inc. — 9.87%
Bellevue Group AG — 2.04%
Janus Henderson Group PLC — 1.37%
Bank of New York Mellon Corp — 0.93%
Jacobs Levy Equity Management Inc. — 0.71%
Allspring Global Investments Holdings LLC — 0.51%
Learn More about top institutional investors of Neurocrine Biosciences stock.
Which institutional investors are selling Neurocrine Biosciences stock?: During the previous quarter, NBIX stock was sold by these institutional investors:
Los Angeles Capital Management LLC
Bellevue Group AG
Janus Henderson Group PLC
Scout Investments Inc.
Sarissa Capital Management LP
Jennison Associates LLC
Westfield Capital Management Co. LP
Bank of New York Mellon Corp
During the previous year, company insiders that have sold Neurocrine Biosciences company stock include:
Neurocrine Biosciences Inc (Major Shareholder)
Kevin Charles Gorman (CEO)
Gary A Lyons (Director)
Kyle Gano (Insider)
William H Rastetter (Director)
Eric Benevich (Insider)
Darin Lippoldt (Insider)
Matt Abernethy (CFO)
Eiry Roberts (Insider)
Richard F Pops (Director)
Stephen A Sherwin (Director)
Malcolm Lloyd-Smith (Insider)
Julie Cooke (Insider)
Jude Onyia (Insider)
Ingrid Delaet (Insider)
Learn More investors selling Neurocrine Biosciences stock.
Which institutional investors are buying Neurocrine Biosciences stock?: Within the previous quarter, NBIX stock was bought by institutional investors including:
Vanguard Group Inc.
Iron Triangle Partners LP
BNP Paribas Financial Markets
Canada Pension Plan Investment Board
Allspring Global Investments Holdings LLC
Allspring Global Investments Holdings LLC
Vident Advisory LLC
Van ECK Associates Corp